Association of Statin Use With Overall and Cancer Survival

Ahern, Thomas P.; Borgquist, Signe; Cronin‐Fenton, Deirdre

doi:10.1001/jamaoncol.2018.0733

Cited by 1 publication

(1 citation statement)

References 5 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared with the positive findings in previous observational studies, neither 3-year cancer-specific survival nor overall survival was improved in patients who started the statin therapy within 6 months during postdiagnosis ( Emilsson et al, 2018 ). Nevertheless, although this emulated trial yielded the negative influence of selection bias on evaluating the statin use and cancer survival, it should not discourage the enthusiasm for conducting trials of statins in cancer prevention and survival since statin repurposing was expected to be a more cost-effective way compared to some other newly modalities of cancer treatment ( Ahern et al, 2018 ; Chan et al, 2018 ).…”

Section: Discussionmentioning

confidence: 99%

Assessing the role of lipid-lowering therapy on multi-cancer prevention: A mendelian randomization study

Wei

Liu

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Statin use for cancer prevention has raised wide attention but the conclusions are still controversial. Whether statins use have exact causal effects on cancer prevention remains unclear.Methods: Based on the Genome-Wide Association Studies (GWAS) datasets from the large prospective UK Biobank and other consortium databases, two-sample mendelian randomization (MR) analysis was conducted to explore the causal effects of statins use on varied site-specific cancer risks. Five MR methods were applied to investigate the causality. The stability, heterogeneity, and pleiotropy of MR results were also evaluated.Results: The atorvastatin use could increase the risk of colorectal cancer (odd ratio (OR) = 1.041, p = 0.035 by fixed-effects inverse variance weighted (IVW) method (IVWFE), OR = 1.086, p = 0.005 by weighted median; OR = 1.101, p = 0.048 by weighted mode, respectively). According to the weighted median and weighted mode, atorvastatin could modestly decrease the risk of liver cell cancer (OR = 0.989, p = 0.049, and OR = 0.984, p = 0.004, respectively) and head and neck cancer (OR = 0.972, p = 0.020). Besides, rosuvastatin use could reduce the bile duct cancer risk by 5.2% via IVWEF method (OR = 0.948, p = 0.031). No significant causality was determined in simvastatin use and pan-cancers via the IVWFE or multiplicative random-effects IVW (IVWMRE) method if applicable (p > 0.05). There was no horizontal pleiotropy observed in the MR analysis and the leave-one-out analysis proved the stability of the results.Conclusion: The causalities between statin use and cancer risk were only observed in colorectal cancer and bile duct cancer in the European ancestry population. Future works are warranted to provide more robust evidence for supporting statin repurposing for cancer prevention.

show abstract

Section: Discussionmentioning

confidence: 99%